What is Mycorena?
Mycorena operates at the intersection of biotechnology and food science, specializing in the development of Promyc, a 100% natural fermented mycoprotein. By leveraging advanced fermentation processes, the company provides high-protein, sustainable meat alternatives tailored for the B2B food industry. Their business model emphasizes co-creation, allowing partners to integrate high-quality, plant-based protein structures into diverse consumer product lines. This approach not only addresses the global demand for sustainable nutrition but also optimizes supply chains by utilizing locally sourced ingredients to create scalable, nutrient-dense food solutions.
How much funding has Mycorena raised?
Mycorena has raised a total of $26.8M across 1 funding round:
Series A
$26.8M
Series A (2022): $26.8M, investors not publicly disclosed
Key Investors in Mycorena
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Mycorena?
With this major strategic investment, Mycorena is poised to transition from a development-focused entity to a market-scaling powerhouse. The capital will likely be deployed to expand production infrastructure, enhance R&D capabilities for new mycoprotein applications, and strengthen commercial partnerships within the global food sector. As the enterprise-level funding provides the necessary runway, the company is expected to focus on optimizing its fermentation efficiency and broadening its distribution footprint, effectively positioning itself as a leader in the alternative protein market. Future growth will likely hinge on the successful integration of their proprietary technology into mainstream food manufacturing pipelines, further solidifying their competitive advantage in the sustainable food landscape.
See full Mycorena company page
